•     By Kevin E. Noonan

    Uspto_seal_no_background
    Review of the new "examination support document" rule promulgated in 37 C.F.R. § 1.265 on August 21, 2007 strongly suggested that the purpose of the rule was not to facilitate submission of relevant prior art as an improvement over current Information Disclosure Statement provisions, but rather to provide strong encouragement (coming close to coercion) for applicants to file no more than 5 independent and 25 total claims (see previous post on Rule 265).  The bases for this were the stringent requirements not only for information but for applicants to characterize the information with regard to patentability, coupled with a complete lack of any effort by the Patent Office to modify the duty of disclosure to permit an applicant or counsel to submit an ESD without the certainty of being accused of inequitable conduct.  This impression was reinforced by the guidelines issued from the Patent and Trademark Office on September 6, 2007.

    The guidelines are directed to the requirements of the rule and explicate (generally) what will (and what will not) satisfy the rule.  Some highlights:

    1.  The Office suggests that the preexamination search be performed giving the limitations in each of the independent and dependent claims their "broadest reasonable interpretation."  Moreover, the limitations in dependent claims should be searched independently of their combination with the limitations or elements of the independent claims.  For means-(or step-)plus-function claims, the search must encompass the embodiments explicitly-disclosed in the specification and, of course, "equivalents thereof"; it can be contemplated that any such search will be available during litigation to assert an estoppel of the embodiments satisfying the means-plus-function claim.

    2.  The Office also suggests that applicants (and their representatives) include "disclosed but unclaimed features" that the applicant may wish to incorporate in their claims, in order to avoid the need to perform a supplemental search.  Thus, the extent of this search effectively extends past the scope of the claims to encompass whatever is disclosed in the specification.  Unmentioned is whether the search must also encompass all that is know to one of ordinary skill in the art (also unmentioned is the crystal-ball, tea-leaf-reading character of this requirement).

    3.  Foreign patent office searches "may" not "automatically" satisfy the requirement, but it is clear from what is required for such a search to affirmatively satisfy the requirement that such a search will never suffice.  Of course, the rule does not abrogate an applicant’s duty of candor in disclosing whatever a foreign patent office issues in a search report.  And an earlier search on a non-provisional application will not necessarily suffice, either; the guidelines do not state whether Examiner-conducted searches in earlier-filed applications are deemed to be insufficient by this rule.

    4.  The rule requires a large amount of detail with respect to identifying the field of search and the search terms used; reliance on the M.P.E.P. standards may be (but are not necessarily) sufficient.  The guidelines refer applicants to M.P.E.P. §§ 904-904.03, and to a web-based search template (which can be found here).

    5.  The Office can also deem a search insufficient if it determines that there is closer prior art than what was provided by the applicant.  It is unclear from the guidelines how an applicant could cure the deficiency, other than performing the patentability analysis using this newly-cited art, but it certainly increases the inequitable conduct exposure.  This is particularly true if the art is applicant’s own art; the existence of a genuine dispute between the applicant and the office over the scope of any said art will disappear during a post-hoc inequitable conduct accusation.

    6.  While providing a number of web-based resources for applicants trying to comply with the search rules (for example, the Manual of Classification, the guidance provided for ESD’s with regard to accelerated examination, and a more extensive review of the classification system), the guidelines also suggest that the search be extended to "all probable classes and subclasses relevant to the subject matter of each claim," with no guidance on determining the metes and bounds of what is "probable."

    7.  Classification and text searches are recommended, however, classification searches cannot be limited by any text query.  This requirement appears to require an entire class and subclass be reviewed and references eliminated one by one from the search after review.  Text searches for PCT documents should encompass the standards set forth here.

    8.  "Other sources" of art outside the scope of the searches set forth in the guidelines include:

    • Applicant’s own work including references by at least one of the inventors.
    • References cited in any prior-filed application in which a benefit or priority is claimed.
    • References cited in an international search report of a national stage application.

    9.  Turning to the requirement that the ESD identify references "most closely related" to the claims, the Office asserts that these references will be those that disclose the most number of limitations in an independent claim; or a limitation in an independent claim not found in any other reference; or a limitation in a dependent claim not shown in any other reference.  However, if such a reference has a priority or publication date less than one year before the applicant’s filing or priority date, additional references should be identified that have a publication or priority date more than one year before the applicant’s filing or priority date, even if that disclosure is "less closely related" to the claims.  However, the duty of disclosure requires that other art, "less closely related" to the claims, be submitted in an IDS, including inter alia art cited in foreign or International search reports.

    10.  The Office suggests the applicant "map" (presumably using a claim chart) the portions of any reference cited in an ESD that discloses any limitation in an independent or dependent claim.  Only one portion of a reference need be recited, unless any second or other reference would not be "apparent" to the Examiner.  A requirement that the Examiner read the reference is not contained in the guidelines.

    11.  With regard to the detailed explanation of patentability, the guidelines suggest that:

    The ESD must set out with particularity, by reference to one or more specific claim limitations, why the claimed subject matter is not described in the references, taken as a whole.  The applicant must explain why a person of ordinary skill in the art would not have combined the features disclosed in one reference with the features disclosed in another reference to arrive at the claimed subject matter.  The applicant must also explain why the claim limitations of the independent claims render the claimed subject matter novel and non-obvious over the cited prior art.

    It is unclear what evidence is required to establish what one of ordinary skill in the art would not have considered in the motivation to combine vel non, or what would be considered novel or non-obvious.

    12.  The guidelines also make plain that, where an application claims priority to an earlier application, the requirement for showing explicit support for limitations in all independent and dependent claims extends to all such priority applications.

    13.  The duty to file an ESD, and all its requirements, is ongoing and arises when new art is uncovered and when amendments are made to the claims.  A supplemental ESD can be required under these circumstances.

    These guidelines are clearly intended to more fully explain how an applicant can comply with the ESD rules.  Whether intentional or not, what they most clearly explain is that an applicant should avoid filing an ESD under any circumstances.  This may be the intended consequence after all.

    For additional articles in this series, please see:

    For additional information on this and other related topics, please see:

  •     By Donald Zuhn

    Uspto_seal_2
    The U.S. Patent and Trademark Office announced today that it has begun a pilot project with the Swedish Patent and Registration Office (PRV) in an attempt to reduce the USPTO’s growing backlog of U.S. national applications waiting to be examined.  The pilot program will test the feasibility of having the PRV process international applications filed with the USPTO under the Patent Cooperation Treaty.  In particular, the PRV will search and examine 50 PCT Chapter I applications covering a range of technologies, and the USPTO will then review the PRV’s work to ensure that it meets USPTO standards.

    The USPTO noted in its release that each year it receives more than 50,000 PCT international applications and more than 400,000 national applications.  The Patent Office hopes that by outsourcing the search and examination of international applications, the Office can redirect resources to its backlog of approximately 750,000 U.S. national applications.

    Logo_orig_eng_2

  •     By Donald Zuhn

    Uspto_seal
    On August 30, 2007, the U.S. Patent and Trademark Office announced that publicly available final decisions of the Board of Patent Appeals and Interferences (BPAI) posted on the BPAI’s Final Decision FOIA web page will now be text searchable.

  •     By Jason Derry —

    Alligator_bioscience_ablogo_low_2
    Alligator Bioscience has announced that it has entered a collaborative agreement with SARomics.  SARomics is a research company that provides its partners with in silico drug discovery platforms in the fields of structural biology, computational chemistry, and biostatistics.  In particular, SARomics offers many services that help its partners in the drug discovery process, including protein homology modeling, structure-based drug design, virtual screening, Saromics_webbanner3
    ligand-based drug design, QSAR analysis, experimental design, and high throughput data processing and data mining.  Alligator Bioscience focuses on developing and optimizing therapeutic and diagnostic proteins using its proprietary in vitro protein evolution technology.

    Jason Derry, Ph.D., who graduated with honors from DePaul University
    College of Law, is a molecular biologist and founding author of Patent Docs.

  •     By Sherri Oslick

    Gavel_15
    About
    Court Report:  Each week we will report briefly on recently filed
    biotech and pharma cases, and a few interesting cases will be selected
    for periodic monitoring.


    Purdue Pharma LP et al. v. Apotex Inc. et al.

    1:07-cv-00549; filed September 12, 2007 in the District Court of Delaware

    Infringement of U.S. Patent No. 5,508,042 ("Controlled Release Oxycodone Compositions," issued April 16, 1996) following a paragraph IV certification as part of Apotex’s filing of an ANDA to manufacture a generic version of Purdue Pharma’s OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.


    Hoffmann-La Roche Inc. v. Gate Pharmaceuticals et al.

    2:07-cv-04285; filed September 7, 2007 in the District Court of New Jersey

    Hoffmann-La Roche Inc. v. Teva Pharmaceurticals USA, Inc. et al.
    2:07-cv-04284; filed September 7, 2007 in the District Court of New Jersey

    Hoffman-La Roche Inc. v. Mutual Pharmaceutical Company, Inc. et al.
    2:07-cv-04350; filed September 11, 2007 in the District Court of New Jersey

    The complaints in these cases are substantially similar.  Infringement of U.S. Patent Nos. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007) and 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001) following a paragraph IV certification as part of defendants’ filing of an ANDA to manufacture a generic version of Roche’s Boniva® (ibandronate sodium, used to treat post-menopausal osteoporosis).  View the Gate Pharmaceuticals complaint here.

  • Calendar_14
    September 18, 2007 – Trying a Patent Validity Case in a Post-KSR World (Practising Law Institute)

    September 18-19, 2007 – Pharma/Biotech Patent Boot Camp (American Conference Institute) – San Francisco, IL***

    September 19, 2007 – Final USPTO Rules on Claims and Continuations (Practising Law Institute)

    September 20, 2007 – KSR International Co. v. Teleflex, Inc.: Where Do We Stand Five Months Out? (West LEGALworks)

    September 24-25, 2007 – Biosimilars 2007 (Scherago International, Inc.) – George Washington University, Washington, D.C.

    September 26-27, 2007 – Advanced Forum on Biotech Patents (American Conference Institute) – Boston, MA***

    September 27-28, 2007 – Biotechnology: Business and Legal Developments (Law Seminars International) – Seattle, WA

    October 10-12, 2007 – Stem Cells European Business Summit – Edinburgh, Scotland

    October 12, 2007 – Intellectual Property Law Summit 2007 (West LEGALWorks and Intellectual Property Law Association of Chicago) – Chicago, IL

    October 25-26, 2007 – Biotech and Pharma Public-Private Partnerships Forum (American Conference Institute) – Washington, D.C.***

    October 25-27, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) – Palm Springs, CA

    November 13-15, 2007 – Pharma and Biotech Collaborative Agreements (American Conference Institute) – New York, NY***

    ***Patent Docs is a media sponsor of this conference or CLE.

  •     By Donald Zuhn

    Uspto_seal
    On September 4, 2007, the U.S. Patent and Trademark Office announced that it has initiated a Patent Prosecution Highway (PPH) pilot program with the United Kingdom Intellectual Property Office (UK IPO).  The two offices are now accepting applications for participation in the pilot PPH, which permits an applicant having an application whose claims have been allowed by one office to fast track the examination of an application in the other office, such that the latter application would be examined out of turn.  In particular, an applicant receiving a ruling from either the UK IPO or the USPTO that at least one claim in an application is patentable may request that the other office fast track the examination of corresponding claims in the corresponding application.

    According to the USPTO announcement, the pilot PPH will "leverage fast-track patent examination in both offices to allow applicants in both countries to obtain corresponding patents faster and more efficiently," and "permit each office to benefit from work previously done by the other office, in turn reducing examination workload and improving patent quality."  UK Intellectual Property Office Ian Fletcher labeled the program "a further step towards a global patent prosecution highway network."

    The USPTO-UK IPO initiative parallels a similar pilot PPH involving the Japan Patent Office and the USPTO, which was begun in July 2006.

    The pilot program is scheduled to run until September 4, 2008.  Additional information regarding the USPTO-UK IPO pilot PPH program, including the conditions for eligibility, can be found at the USPTO website and at the UK IPO website.

    For additional information regarding this topic, please see:

  •     By Sherri Oslick

    Teva_1
    On Tuesday, Teva Pharmaceuticals and Dr. Reddy’s Laboratories filed a joint stipulation of dismissal in their pending lawsuit over generic sertraline hydrochloride (the API in Pfizer’s Zoloft®, used to treat depression).  The suit, originally filed on February 1, 2007 in the District Court of New Jersey, was dismissed without prejudice, with the stipulation of dismissal noting that Dr. Reddy’s is not selling, and has Zoloft_ad_1_3
    no current intention to sell, generic Zoloft® to anyone other than Teva, and that Dr. Reddy’s will provide Teva with 30 days advance notice of any importation, sale, offer to sell, or use of sertraline hydrochloride finished product or API.

    Drreddys_logo
    The settlement of Teva’s suit against Dr. Reddy’s ends just one of many pending actions filed by Teva earlier this year surrounding the manufacture of generic Zoloft®.  Information on these actions can be found in our previous reports of February 25, March 4, April 15, and June 3, 2007.  At issue in each of these cases, including the action against Dr. Reddy’s, are four U.S. patents:  6,600,073 ("Methods for Preparation of Sertraline Hydrochloride Polymorphs," issued July 29, 2003), 6,500,987 ("Sertraline Hydrochloride Polymorphs," issued December 31, 2002), 6,495,721 ("Sertraline Hydrochloride Form II and Methods for the Preparation Thereof," issued December 17, 2002), and 6,897,340 ("Processes for Preparation of Polymorphic Form II of Sertraline Hydrochloride," issued May 24, 2005), all directed to methods of manufacturing crystalline forms of sertraline hydrochloride.

  •     By Kevin E. Noonan

    Uspto_seal_no_background
    On August 21, 2007, the U.S. Patent and Trademark Office published new
    rules concerning continuation and claims practice that will undoubtedly
    have a profound effect on the way patent attorneys and agents prosecute
    applications before the Patent Office.  In view of the 128-page Federal Register notice
    regarding the new rules, the Patent Office’s nearly two hour webcast on
    August 23, 2007 (and the webcast’s accompanying 109-page presentation), and the Office’s 45-page list of Frequently Asked Questions, Patent Docs
    believes it may be helpful to examine the rules piece-by-piece in an
    attempt to identify areas where patent attorneys and agents will need
    to modify their patent prosecution practice.


    37 C.F.R. § 1.265:

    Federal_register_cover
    One of the more controversial (and problematic) of the new rules promulgated by the U.S. Patent and Trademark Office on August 21, 2007 is the requirement that an applicant submit an examination support document (ESD) for any application having more than 5 independent claims or 25 total claims (see 5/25 Limit on Claims).  This rule is part of a broader effort to shift the examination burden from the Patent Office to applicants, which is a key motivation for the new rules (the other motivation, of course, being to reduce the number of applications pending in the Office, regardless of the effect on protecting innovation).  Although Office representatives indicated during "town hall" meetings that new rules regarding the Rule 56 duty of candor would be developed to address the enormous increase in the risk of inequitable conduct accusations occasioned by filing an ESD, no revisions to Rule 56 are forthcoming.  This severely limits the usefulness of the ESD practice, which may be in line with the Office’s purpose for creating the requirement in the first place.

    The ESD portion of the new rules (37 C.F.R. § 1.265) has a number of specific provisions in addition to providing the Office with prior art known to the applicant (which has been the burden imposed by Rule 56 before now).  These include the following:

    1.  An applicant is required to perform (or have performed on her behalf) a preexamination search and to submit an affirmative statement that a search has been performed.  Included in the statement must be the field of search as defined by the PTO’s class and subclass definitions, as well as the date of the search.  For chemical and biotechnology applications, an applicant must also submit the chemical structure or sequence searched, as well as identifying the database searched (such as Chemical Abstracts or GenBank).  Copies of all references (except U.S. patents and applications) must be submitted.

    The rules require a search of U.S. and foreign patents and applications, as well as any other prior art source such as the scientific literature.  Failure to cite any references in these categories must be accompanied by a statement justifying with "reasonable certainty" that no more pertinent reference would be found in the eliminated prior art source than have been found elsewhere.  Unresolved by the rule is whether an Examiner will be required to duplicate the search (which would reduce the benefits to the Office resulting from the rule) or rely upon it; such reliance would only bolster any inequitable conduct allegations made against any claims granted as the result, and raises questions on the legitimacy of the search fees charged by the Office as part of the filing fee for a new application.

    2.  The results of the search must be provided as a list of references.  Unlike current Information Disclosure Statement (IDS) practice, however, an applicant must identify the references deemed (by the applicant) as being "most closely related" to the subject matter of each of the claims.  This list must contain substantially the same bibliographic information on each reference (title, author/inventor, publication date, priority date, etc.) as is now required for an IDS.

    Unlike an IDS, the new rule requires an applicant to go on the record with particularity by characterizing the significance of each reference to each claim.  No doubt there will be instances where this is clear and unambiguous; however, the frequency with which charges of inequitable conduct are raised under the less specific disclosure rules in place prior to these new rules suggests that any information provided according to this portion of the rule will expose patent practitioners to a much greater risk of these allegations.  Filing an ESD will also give patent infringement defendants a much greater opportunity to elicit information at deposition from the prosecuting attorney.

    3.  Not satisfied with requiring specific identification of the "most closely related" references, the new rules also require an applicant to identify all of the limitations in each of the claims that are contained in or disclosed by the reference.

    The purpose of this requirement is clearly to improve Examiner efficiency, but at the risk of serious second-guessing during litigation, particularly in instance where additional limitations are added during prosecution.

    (This portion of the new rules do not apply to small entities as defined
    by the rule.  These include businesses not having more than 500
    employees, not-for-profit enterprises not "dominant in its field," and
    government entities from populations of 50,000 or less.)

    4.  Not satisfied with the above requirements, the rules also require an applicant to provide a "detailed explanation" of why each of the independent claims is patentable over the cited art.

    This provision completes the burden-shifting from the Office to the applicant, and raises the question of whether the rule is in compliance with the provisions of 35 U.S.C. § 102 which state that an applicant is entitled to a patent unless there is novelty-destroying prior art in one of the seven subcategories of the statute.

    5.  Finally, an applicant is required to provide a showing of support in the specification under 35 U.S.C. § 112, first paragraph, for "each limitation in each of the claims."  Where there is a priority claim made, this showing must be provided for each of the priority applications.

    With this provision of the rule, the Office has abandoned any pretense that Examiners are required to read the applications under examination, something known to be a pretense for anyone who has experienced a rejection under 35 U.S.C. § 112 based on the absence of a term definition or explicit support where the specification clearly contains the required disclosure.

    6.  The filing of an Information Disclosure Statement does not satisfy the rule.  In addition, should the Office determine that an ESD is insufficient, an applicant will be notified and given a non-extendable, two-month period to file a corrected or supplemental ESD.  Alternatively, the claims can be amended to fall within the 5/25 rule, thereby removing the ESD requirement.

    It is unlikely that the alternative is truly a viable one; having submitted an ESD in the first place, an applicant is exposed to the increased likelihood of an inequitable conduct charge since the ESD is part of the prosecution history.  Moreover, any defect in the ESD resulting in a determination that it is "insufficient" will not be cured by amending the claims to remove the ESD requirement.

    In view of the liability that will predictably attach by filing an ESD, it would be folly for any applicant to comply with this rule except in cases where there is objectively no prior art to be cited.  Although such instances may exist (for example, where an International Search Report provides only "A" references), they can be expected to be both unlikely and rare.  The potential for a later determination that a patent is unenforceable for inequitable conduct in any other circumstance should severely limit the instances where ESDs are filed, further influencing applicant behavior to conform to the 5/25 rule.  The Office’s failure to address the Rule 56 changes needed to enable applicants to comply with the rule suggests that the purpose of the rule is merely to provide a sufficient incentive for applicants to restrict their claims to 5 independent claims and 25 total claims.  The Office’s use of the ESD rules to force compliance with the 5/25 limitation is yet another reason for practitioners to question the Office’s honesty and good faith in promulgating these rules.

    For additional articles in this series, please see:

    For additional information on this and other related topics, please see:

    Changes to Rules 265:

    (a) An examination support document as used in this part means a document that includes the following:

    (1) A statement that a preexamination search in compliance with paragraph (b) of this section was conducted, including an identification of the field of search by United States class and subclass and the date of the search, where applicable, and, for database searches, the search logic or chemical structure or sequence used as a query, the name of the file or files searched and the database service, and the date of the search;
    (2) A listing of the reference or references deemed most closely related to the subject matter of each of the claims (whether in independent or dependent form) in compliance with paragraph (c) of this section;
    (3) For each reference cited, an identification of all of the limitations of each of the claims (whether in independent or dependent form) that are disclosed by the reference;
    (4) A detailed explanation particularly pointing out how each of the independent claims is patentable over the cited references; and
    (5) A showing of where each limitation of each of the claims (whether in independent or dependent form) finds support under the first paragraph of 35 U.S.C. 112 in the written description of the specification. If the application claims the benefit of one or more applications under title 35, United States Code, the showing must also include where each limitation of each of the claims finds support under the first paragraph of 35 U.S.C. 112 in each such priority or benefit application in which such support exists.

    (b) The preexamination search referred to in paragraph (a)(1) of this section must involve U.S. patents and patent application publications, foreign patent documents, and non-patent literature, unless the applicant justifies with reasonable certainty that no references more pertinent than those already identified are likely to be found in the eliminated source and includes such a justification with the statement required by paragraph (a)(1) of this section. The preexamination search referred to in paragraph (a)(1) of this section must be directed to the claimed invention and encompass all of the limitations of each of the claims (whether in independent or dependent form), giving the claims the broadest reasonable interpretation.
    (c) The listing of references required under paragraph (a)(2) of this section as part of an examination support document must include a list identifying each of the cited references in compliance with paragraphs (c)(1) and (c)(2) of this section, a copy of each reference if required by paragraph (c)(3) of this section, and each English language translation if required by paragraph (c)(4) of this section.

    (1) The list of cited references must itemize U.S. patents and U.S. patent application publications (including international applications designating the U.S.) in a section separate from the list of other references. Each page of the list of the cited references must include:
    (i) The application number, if known, of the application in which the examination support document is being filed;
    (ii) A column that provides a space next to each cited reference for the examiner’s initials; and
    (iii) A heading that clearly indicates that the list is part of an examination support document listing of references.
    (2) The list of cited references must identify each cited reference as follows:

    (i) Each U.S. patent must be identified by first named patentee, patent number, and issue date.
    (ii) Each U.S. patent application publication must be identified by applicant, patent application publication number, and publication date.
    (iii) Each U.S. application must be identified by the applicant, application number, and filing date.
    (iv) Each foreign patent or published foreign patent application must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.
    (v) Each publication must be identified by publisher (e.g., name of journal), author (if any), title, relevant pages of the publication, date, and place of publication.

    (3) The listing of references required under paragraph (a)(2) of this section must also be accompanied by a legible copy of each cited reference, except for references that are U.S. patents or U.S. patent application publications.
    (4) If a non-English language document is being cited in the listing of references required under paragraph (a)(2) of this section as part of an examination support document, any existing English language translation of the non-English language document must also be submitted if the translation is within the possession, custody, or control of, or is readily available to any individual identified in § 1.56(c).

    (d) If an information disclosure statement is filed in an application in which an examination support document is required and has been filed, the applicant must also file a supplemental examination support document addressing the reference or references in the manner required under paragraphs (a)(3) and (a)(4) of this section unless the information disclosure statement cites only references that are less closely related to the subject matter of one or more claims (whether in independent or dependent form) than the references cited in the examination support document listing of references under paragraph (a)(2) of this section.
    (e) If an examination support document is required, but the examination support document or preexamination search is deemed to be insufficient, or the claims have been amended such that the examination support document no longer covers each of the claims, applicant will be notified and given a two-month time period that is not extendable under § 1.136(a) within which, to avoid abandonment of the application, the applicant must:

    (1) File a corrected or supplemental examination support document in compliance with this section that covers each of the claims (whether in independent or dependent form); or
    (2) Amend the application such that it contains no more than five independent claims and no more than twenty-five total claims.

    (f) An examination support document, or a corrected or supplemental examination support document, is not required to comply with the requirements set forth in paragraph (a)(3) of this section if the examination support document is accompanied by a certification that any rights in the application have not been assigned, granted, conveyed, or licensed, and there is no obligation under contract or law to assign, grant, convey, or license any rights in the application, other than a security interest that has not been defaulted upon, to any entity other than:

    (1) A business or other concern:

    (i) Whose number of employees, including affiliates, does not exceed 500 persons; and
    (ii) Which has not assigned, granted, conveyed, or licensed (and is under no obligation to do so) any rights in the invention to any person who made it and could not be classified as an independent inventor, or to any concern which would not qualify as a non-profit organization or a small business concern under paragraph (f)(1)(i) of this section.

    (2) A not-for-profit enterprise which is independently owned and operated and is not dominant in its field; or
    (3) A government of a city, county, town, township, village, school district, or special district, with a population of less than fifty thousand.

  •     By Kevin E. Noonan

    Aven_logo
    The contours of the Federal Circuit’s obviousness jurisprudence post-KSR continued to be revealed today with the CAFC’s decision in Aventis Pharma Deutschland GmbH v. Lupin, Ltd.  The Federal Circuit reversed a finding in the District Court that the Aventis claims were non-obvious, based on what it termed a "too rigid" application of the CAFC’s teaching-suggestion-motivation (TSM) test, which was repudiated by the Supreme Court in KSR Int’l Co. v. Teleflex, Inc.

    Index_logo
    The case involves Lupin’s filing of an Abbreviated New Drug Application (ANDA) for a generic version of the blood pressure medication ramipril (marketed by Aventis’ co-plaintiff King Pharmaceuticals, Inc. as Altace®).  Ramipril is an angiotensin-converting enzyme (ACE) inhibitor for treating high blood pressure by "inhibit[ing] a biochemical pathway that constricts blood vessels."  The District Court found Lupin to be an infringer on summary 81c2
    judgment under the doctrine of equivalents, and also found after a bench trial that the asserted claims of the patent-in-suit, U.S. Patent No. 5,061,722 were not invalid for obviousness.  The pharmaceutical compound Ramipril is one of a plurality of stereoisomers of the chemical compound represented below, where the stereoisomeric conformation of all the chiral carbon atoms designated by an asterisk are in the (S) configuration:

    Compound1

    Thus, the pharmaceutical ramipril is one of 32 different stereoisomers; it is known as the "5(S)" or "SSSSS" enantiomer.

    Claim 1 of the ‘722 reads as follows:

    1.  A compound of the formula

    Compound2

    or a physiologically acceptable salt thereof, wherein R2 is hydrogen, methyl, ethyl, or benzyl, and wherein hydrogen atoms on the ring carbon atoms in the 1- and 5-positions are in the cis-configuration relative to one another, the carboxyl group on the ring carbon atom in the 3-position is in the endo position relative to the bicyclic ring system, and the chirality centers in the chain and on the ring carbon atom in the 3-position all have the S-configuration, said compound or salt being substantially free of other isomers.

    This claim is limited to the 5(S) enantiomer.

    Prior art ACE inhibitors, including a naturally-occurring molecule isolated from snake venom and several synthetic analogues, were structurally similar to ramipril, and importantly had multiple chiral carbon atoms all in the S configuration.  The "all S" enantiomer of the most closely-related molecule, enalapril (produced by Merck) had been described as having 700 times the biological activity of the "SSR" stereoisomer; the prior art described how the SSS isomer of enalapril could be separated from the other seven stereoisomeric species of that compound.  There was also evidence that a Schering scientist had conceived of the ramipril chemical structure and filed and obtained U.S. patents on her invention.  However, these patents do not disclose the active stereochemical conformation of the molecule, and the experimental examples in these patents would be expected to produce less than the complete complement of 32 stereoisomers (perhaps as few as four of them).  There was also evidence that the Schering scientist thereafter produced a mixture of the SSSSS and SSSSR enantiomers.  All this work occurred prior to Aventis producing ramipril for the first time, but since the 5(S) enantiomer was not known in the prior art, Aventis’ claims were novel over this art.

    There was one more interesting feature of the factual predicate of the lawsuit.  Aventis licensed the Schering patents, and when the Patent and Trademark Office declared an interference between the Schering patents and Aventis’ applications, the interference settled.  Thus, the invalidity question did not arise during the interference.  However, Aventis did concede priority as to the generic ramipril structure, i.e., without specifying the stereochemical configuration of the active ramapril enantiomer.

    The District Court found that, on this record, Lupin had failed to present clear and convincing evidence that the patent was invalid for obviousness, but indicated that it was a close case, decided mainly because of the requirement that invalidity be proven by clear and convincing evidence.

    The Federal Circuit reversed in a decision by Judge Linn (joined by Judge Mayer and Judge Robertson of the D.C. District Court, sitting by designation).  Judge Linn asserted that the prior art contained "a litany of potential prior art references" besides the ones asserted at trial.  However, the Federal Circuit focused its analysis on the prior art relating to the Merck compound elanapril, and the Schering invention of the mixture of ramapril stereoisomers, including the mixture of the SSSSS and SSSSR enantiomers.  The CAFC noted that the District Court’s reasoning in deciding that the claims were not obvious was based primarily on a lack of clear and convincing evidence of any motivation in the art to separate the SSSSS isomer, as required by Aventis’ patent claims in suit.

    This was error, according to the Federal Circuit.  The CAFC cited KSR for the principle that applying the TSM test in a "rigid and mandatory" fashion was erroneous, and for the proposition that it is "necessary to show ‘some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness,’ but such reasoning ‘need not seek out precise teachings directed to the specific subject matter of the challenged claim.’"  The Federal Circuit said that requiring an explicit teaching to separate the SSSSS enantiomer as the active species was "precisely the sort of rigid application of the TSM test that was criticized in KSR."

    The CAFC focused on the "structural similarity" between the claimed compounds and the prior art.  Explicit teaching of a particular utility is not required, the Federal Circuit said, but there must be sufficient structural similarity to show a "sufficiently close relationship" that the skilled worker would expect the new compound to have "similar properties" to the prior art compound(s).  And the Federal Circuit’s precedents held that structural similarity was enough to establish a prima facie case of obviousness.  This analysis extends to mixtures of enantiomers, because the existence of the mixture is not sufficient in every case to render the separated enantiomer non-obvious.  For example, the Federal Circuit said a separated enantiomer would be non-obviousness in situations where the existence of a particular enantiomer or its identity as an active ingredient were unknown, or that the art does not teach how to separate the mixture.

    However, here the Federal Circuit found ample evidence of invalidity due to obviousness.  For example, the CAFC found that the skilled worker would have known how to separate the SSSSS enantiomer of ramipril and would have expected the greater activity results found for the Schering mixture in the prior art.  In particular, the Federal Circuit found that the two enantiomers in the Schering mixture, SSSSS and SSSSR, differed at only one position, and that the earlier prior art compounds were all consistent with the "all (S)" enantiomer having the greatest potency.  The art, in particular certain of Schering’s prior patents, described the SSS configuration as being 700-fold more potent and described how to isolate the 5(S) enantiomer from the other stereoisomers.  Moreover, the differences in potency shown for the two enantiomers of elanapril (SSS and SSR) would have lead the skilled worker to expect the activity of ramapril to reside preferentially in the SSSSS enantiomer, due to the close structural similarity between these two molecules.  This evidence was enough to convince the Federal Circuit that Aventis’ claims were obvious in view of the prior art.

    The CAFC also rejected Aventis’ argument for unexpected results, and stated that the proper comparator for analyzing whether Aventis’ results were unexpected was not all 32 of ramipril’s enantiomers but the Schering mixture of the 5(S) and SSSSR enantiomers.

    This case is consistent with the results from Pfizer, Inc. v. Apotex, Inc. and Forest Labs., Inc. v. Ivax Pharm., Inc. and indicates that the Federal Circuit’s reaction to the Supreme Court’s criticism of its jurisprudence in KSR is to emphasize the primacy of structural obviousness in its determinations.  The Federal Circuit also appears to be ready to base its decisions on the factual grounds for a non-obviousness determination, where the standard for reversing (clear error) is higher and any judgments are less likely to be invalidated by the Supreme Court.

    Aventis Pharma Deutschland GmbH v. Lupin, Ltd. (Fed. Cir. 2007) 
    Panel: Circuit Judges Mayer and Linn and District Judge Robertson
    Opinion by Circuit Judge Linn

    Additional information regarding this case can be found at the Orange Book Blog and Patently-O.